Data Limitations Continue To Plague Northera As The NOH Therapy Goes To Its Second Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will ask the Cardiovascular and Renal Drugs Advisory Committee Jan. 14 whether there is a population that showed a better than mean effect for the primary endpoint of dizziness.